Prime Medicine has reported promising initial clinical data from the first-ever trial of a prime-editing therapeutic candidate, showing that a single...
This week's clinical update includes FDA RMAT designation to Beam Therapeutics' BEAM-302 for the treatment of alpha-1 antitrypsin deficiency as well...
Durham-based Precision BioSciences has received IND clearance for PBGENE-HBV, making it the first investigational in vivo gene-editing therapy to...
Eight months after dosing the first patient with BEAM-302, Beam Therapeutics has shared exciting safety and efficacy data indicating that a...
YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...
The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...
The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...
The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...
